Precinical proof-of-concept demonstration of the protective effect of the Administration for 36 days of IMA001 during an acute episode of vaso-occlusion in sickle Townes HbSS mice. IMA001 reduced intravascular hemolysis and inhibited microvascular stasis in animals subjected to an acute hypoxia followed by reoxygenation (8% oxygen for 3 hours and reoxygenation at room air for 1 hour).
Imalia Announces Completion of Clinical Phase of French Pilot Study Evaluating IMA001 in Sickle Cell Disease
Completion of the clinical phase of the monocentric, prospective, open label pilot study conducted